This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2004 Apr 28;291(16):2017-8.

doi: 10.1001/jama.291.16.2017.

Vasopressin receptor antagonists: will the "vaptans" fulfill their promise?

Gary S Francis, W H Wilson Tang

PMID: 15113822
DOI: 10.1001/jama.291.16.2017

Editorial

Vasopressin receptor antagonists: will the "vaptans" fulfill their promise?

Gary S Francis et al. JAMA. 2004.

. 2004 Apr 28;291(16):2017-8.

doi: 10.1001/jama.291.16.2017.

Authors

Gary S Francis, W H Wilson Tang

PMID: 15113822
DOI: 10.1001/jama.291.16.2017

No abstract available

PubMed Disclaimer

Comment on

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Gheorghiade M, et al. JAMA. 2004 Apr 28;291(16):1963-71. doi: 10.1001/jama.291.16.1963. JAMA. 2004. PMID: 15113814 Clinical Trial.

Similar articles

Vasopressin antagonists in heart failure.
Golestaneh L, Talreja A, Le Jemtel TH. Golestaneh L, et al. Curr Heart Fail Rep. 2004 Dec;1(4):190-6. doi: 10.1007/s11897-004-0008-5. Curr Heart Fail Rep. 2004. PMID: 16036044 Review.
Climbing the mountain of acute decompensated heart failure: the EVEREST Trials.
Yancy CW. Yancy CW. JAMA. 2007 Mar 28;297(12):1374-6. doi: 10.1001/jama.297.12.1374. Epub 2007 Mar 25. JAMA. 2007. PMID: 17384439 No abstract available.
Conivaptan: potential therapeutic implications in heart failure.
Chen SY, Abrahams Z, Sokos GG, Mullens W, Hobbs R, Taylor DO, Gonzalez-Stawinski GV. Chen SY, et al. Recent Pat Cardiovasc Drug Discov. 2008 Jun;3(2):137-40. doi: 10.2174/157489008784705403. Recent Pat Cardiovasc Drug Discov. 2008. PMID: 18537764
Vasopressin antagonists in CHF: ready for clinical trials?
Goldsmith SR. Goldsmith SR. Cardiovasc Res. 2002 Apr;54(1):13-5. doi: 10.1016/s0008-6363(02)00250-x. Cardiovasc Res. 2002. PMID: 12062356 No abstract available.
Vasopressin receptor antagonists in the management of acute heart failure.
Tang WH, Bhavnani S, Francis GS. Tang WH, et al. Expert Opin Investig Drugs. 2005 May;14(5):593-600. doi: 10.1517/13543784.14.5.593. Expert Opin Investig Drugs. 2005. PMID: 15926866 Review.

See all similar articles

Cited by

Neurohormonal Therapy for Congestive Heart Failure.
Pritchett AM, Mann DL. Pritchett AM, et al. Curr Treat Options Cardiovasc Med. 2004 Dec;6(6):499-507. doi: 10.1007/s11936-004-0007-6. Curr Treat Options Cardiovasc Med. 2004. PMID: 15496267
Update of treatment of heart failure with reduction of left ventricular ejection fraction.
Aronow WS. Aronow WS. Arch Med Sci Atheroscler Dis. 2016 Oct 17;1(1):e106-e116. doi: 10.5114/amsad.2016.63002. eCollection 2016. Arch Med Sci Atheroscler Dis. 2016. PMID: 28905031 Free PMC article.
Hereditary Nephrogenic Diabetes Insipidus: Pathophysiology and Possible Treatment. An Update.
Milano S, Carmosino M, Gerbino A, Svelto M, Procino G. Milano S, et al. Int J Mol Sci. 2017 Nov 10;18(11):2385. doi: 10.3390/ijms18112385. Int J Mol Sci. 2017. PMID: 29125546 Free PMC article. Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information